| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1352458517690617 |
| P698 | PubMed publication ID | 28156185 |
| P50 | author | Ralf Gold | Q99630149 |
| P2093 | author name string | Alvydas Mikulskis | |
| Robert J Fox | |||
| Katherine T Dawson | |||
| Lakshmi Amaravadi | |||
| Sreeja Gopal | |||
| P2860 | cites work | Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence | Q42157111 |
| Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling. | Q42970191 | ||
| Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters | Q44584654 | ||
| Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism | Q45838667 | ||
| Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action | Q46428789 | ||
| Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis | Q28275399 | ||
| Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection | Q28396785 | ||
| Ethanol-induced HO-1 and NQO1 Are Differentially Regulated by HIF-1α and Nrf2 to Attenuate Inflammatory Cytokine Expression | Q28579518 | ||
| Multiple sclerosis | Q29616022 | ||
| Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis | Q34300614 | ||
| Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. | Q34627230 | ||
| Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. | Q34660955 | ||
| BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress | Q35131372 | ||
| The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy | Q35688436 | ||
| Pharmacokinetics of oral fumarates in healthy subjects. | Q35826385 | ||
| The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress | Q35837805 | ||
| Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. | Q35856171 | ||
| Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis | Q36439880 | ||
| Disease-modifying drugs for multiple sclerosis: current and future aspects | Q36613906 | ||
| Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. | Q36866185 | ||
| Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action | Q37854243 | ||
| Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. | Q37885608 | ||
| Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms | Q38449822 | ||
| The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist | Q39947934 | ||
| Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in mouse beta-cells | Q40126530 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 1352458517690617 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Multiple Sclerosis Journal | Q1952449 |
| P1476 | title | Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies |
| Q62589197 | Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy |
| Q41662736 | Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration? |
| Q40060254 | Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes. |
| Q64246348 | Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions |
| Q46276290 | Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation |
| Q44853889 | Donor variability may mask dimethyl fumarate's effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells |
| Q64902584 | Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis. |
| Q95853289 | Effect of the Lipid Peroxidation Product 4-Hydroxynonenal on Neuroinflammation in Microglial Cells: Protective Role of Quercetin and Monochloropivaloylquercetin |
| Q42229875 | Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation |
| Q89964003 | Electrophile Signaling and Emerging Immuno- and Neuro-modulatory Electrophilic Pharmaceuticals |
| Q47140885 | Modulation of Nrf2 by Olive Oil and Wine Polyphenols and Neuroprotection. |
| Q92817653 | NRF2 as a Therapeutic Target in Neurodegenerative Diseases |
| Q56342367 | Opportunities for Host-targeted Therapies for Malaria |
| Q101237342 | ROS networks: designs, aging, Parkinson's disease and precision therapies |
| Q47194056 | Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells. |
| Q64065809 | The Beneficial and Debilitating Effects of Environmental and Microbial Toxins, Drugs, Organic Solvents and Heavy Metals on the Onset and Progression of Multiple Sclerosis |
| Q55439580 | The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. |
| Q91841392 | Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes |
Search more.